Pure Global
NCT06323239

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Stereotactic Body Radiotherapy (SBRT) and Low-dose Radiotherapy (LDRT) Combined With Programmed Death 1 (PD-1) Antibody and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Single-arm, Phase II Clinical Trial
Sun Yat-sen University·Phase 2·ClinicalTrials.gov·radiationNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
SBRT
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2024
End date
Apr 01, 2028
Enrollment
148 participants
Primary outcome

Progression-free survival

Summary

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to
 evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1
 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06323239
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06323239 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 148 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.